The BRAF inhibitor dabrafenib and MEK inhibitor trametinib have achieved great success in BRAF V600E-mutated anaplastic thyroid carcinoma (ATC) (54). The gene discussed is BRAF; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.